Cell line · CVCL_B079
UWB1.289
Cancer cell line, Homo sapiens. BRCA1 syndrome. 30 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. UWB1.289. Cell lines, record CVCL_B079. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_B079
On this page
Cell line
As Cellosaurus gives it.
- Name
- UWB1.289
- Accession
- CVCL_B079
- RRID
- RRID:CVCL_B079
- Synonyms
- UWB1-289, UWB1289
- Species
- Homo sapiens (Human)
- Sex
- Female
- Age at sampling
- 56Y
- Category
- Cancer cell line
- Diseases
- BRCA1 syndrome (NCIt C36100); Hereditary breast and ovarian cancer syndrome (ORDO Orphanet_145)
- Entry created
- 2012-06-06
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers30
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| BRCA1 Mutation-Recognizing Tetrahedral Framework Nucleic Acid Nanoplatform Enables Coordinated PARP/WEE1 Inhibition and STING-Associated Antitumor Immunity in Ovarian Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting p300 Reverses Acidic Microenvironment-Induced PARP Inhibitor Resistance. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Pharmacologic Profile of ART6043, a First-in-Class Clinical DNA Polymerase Theta Polymerase Domain Inhibitor Potentiating PARP Inhibitor Efficacy. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Multiomics profiling and experiments in preclinical models revealed RAD51-IN-1 as a synergistic potentiator of anlotinib sensitivity. | Sci Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| DHX9 Inhibition Enhances Paclitaxel Sensitivity by Inducing Mitotic Failure in Ovarian and Endometrial Cancers. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Indoleamine 2,3-dioxygenase 1 inhibition reverses cancer-associated fibroblast-mediated immunosuppression in high-grade serous ovarian cancer. | FEBS Open Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The zinc finger domains of PARP-1 are selectively and potently inhibited by the Au(I)-based drugs sodium aurothiomalate and aurothioglucose. | FEBS Lett | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1/2 and MTAP status in breast cancer cells. | Sci Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| SETD1A-dependent EME1 transcription drives PARPi sensitivity in HR deficient tumour cells. | Br J Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell Lines. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 30
See all 30 papersRelatives1
| Relation | Cell line | Accession | Problem |
|---|---|---|---|
| Derived from it | UWB1.289+BRCA1 | CVCL_B078 |
Source Cell lines
Cell banks1
| Cell bank | Catalog number | Status |
|---|---|---|
| ATCC | CRL-2945 |
Source ATCC
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_B079
GET https://conductscience.org/api/cell-lines/v1/CVCL_B079/papers?page=2